• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

GRAS Notices

  • Print
  • Share
  • E-mail
-

The inventory of GRAS notices provides information about GRAS notices filed since 1998, when FDA received its first GRAS notice. As of October 17, 2016, the GRAS final rule (81 FR 54960; August 17, 2016) requires a specific format for a GRAS notice. Prior to that date, FDA processed GRAS notices under the framework of the GRAS proposed rule (62 FR 18938; April 17, 1997). Notices received prior to the effective date of the GRAS final rule provide examples for potential notifiers for the types of information that may support a GRAS conclusion. In the inventory, notices follow the requirements for the format and content of a GRAS notice as of the effective date of the GRAS final rule.

The inventory notes what type of response letter the FDA sent in response to the notice. Notifiers often resubmit notices that FDA previously ceased to evaluate at the notifier’s request, and resubmitted notices commonly receive a letter indicating FDA has no questions, after addressing deficiencies. In the inventory, entries for notices that were later resubmitted link to the newer entry in the final column. Newer entries for notices that were resubmitted include a link to the previous submission below the substance name.

Some GRNs that FDA previously ceased to evaluate at the notifier’s request were later resubmitted as a food additive petition. For each of these cases, the GRN detail page links to the food additive petition.

After issuing a response letter, we may issue a subsequent letter as circumstances warrant. The issue dates of any subsequent letters are listed under the column, "Date of add’l correspondence.”

As of July 2025, FDA is posting notices in a Docket at www.regulations.gov. In these cases, the link for the notices will take you to the document posted at www.regulations.gov. We will update this information approximately monthly. More information about this inventory is available on the GRAS Notice Inventory Introduction page.


Search and display hints:

  • Select the specific GRN number below to view additional details about any GRAS Notice.
  • To sort by a specific field, click on the column header for that field.
  • To browse the records, use the Show All, First/Previous/Next/Last, and Jump To options at the bottom of the data table.
  • To search for a specific substance/term, enter the term in the Search box and select Show Items to display only those records that contain the selected term. (The search results also includes terms not shown on this page, but included in the full record on the detail page.)
  • The search results will return hits of records containing words that include the search term. For example, a search for the color red will return results that include terms such as reduce, ingredient, and cultured. To limit results to only the searched term, place a space before and after the word in the basic search or in the advanced search “this exact phrase” field.
Download GRAS Notices data in Microsoft Excel web format Download data from this searchable database in Excel format. If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Search within these results
Records Found: 1325 Show All Page 1 of 27
GRN No.
(sorted Z-A)
Substance Date of closure FDA's Letter Date of add'l correspondence Resubmitted as GRN No.
  1325
L-ergothioneine produced by Escherichia coli “SF4012” expressing enzymes encoded by the genes from E. coli BL21 (DE3), Leishmania infantum, Mycobacterium tuberculosis, Neurospora crassa, Trichoderma reesei, and Mycolicibacterium smegmatis Pending
  1324
Pongamia (Millettia pinnata (L.)) bean oil Pending
  1323
D-psicose Pending
  1322
Transglutaminase enzyme preparation produced by Escherichia coli expressing a gene encoding transglutaminase from Streptomyces mobaraensis Pending
  1321
A powder prepared from the dried leaves and stems of the Geraldton waxflower (Chamelaucium uncinatum) Pending
  1320
Thaumatin II Pending
  1319
Thaumatin II preparation produced by Komagataella phaffii P-THM-354 Pending
  1318
Enzyme-modified steviol glycosides Pending
  1317
Bifidobacterium animalis subsp. lactis CGMCC18610 Pending
  1316
Saccharomyces cerevisiae BY-1574 expressing a gene encoding an alcohol-O-acyltransferase enzyme from Cucumis melo var. Cantalupensis Pending
  1315
Short-chain chondroitin sulfate oligosaccharides produced from enzymatic hydrolysis of chondroitin sulfate Pending
  1314
Bacillus pumilus SG154 Pending
  1313
Algal oil (≥35% docosahexaenoic acid) from Schizochytrium limacinum CCAP A2 Pending
  1312
Recombinant αS1-casein from Bos taurus produced by Escherichia coli DSM 35603 Pending
  1311
L-theanine produced by Escherichia coli CICC 11189s Pending
  1310
Rebaudioside M produced by enzymatic treatment of rebaudioside A purified from the leaves of Stevia rebaudiana (Bertoni) Bertoni Jul 6, 2026 FDA has no questions (in PDF) (230 kB)
  1309
D-psicose Jul 6, 2026 FDA has no questions (in PDF) (250 kB)
  1308
β-glucan produced by Kluyveromyces marxianus CGMCC 26703 Pending
  1307
Rebaudioside M produced by enzymatic treatment of steviol glycosides purified from the leaves of Stevia rebaudiana (Bertoni) Bertoni Jun 4, 2026 FDA has no questions (in PDF) (236 kB)
  1306
Subtilisin enzyme preparation produced by Bacillus paralicheniformis Pending
  1305
Brazzein preparation produced by Komagataella phaffii GDMCC 70101 expressing a gene encoding for brazzein from Pentadiplandra brazzeana Pending
  1304
Preparation containing at least three bacteriophages (phage) specific to Listeria spp. Pending
  1303
Bifidobacterium animalis subsp. lactis CGMCC5470 May 11, 2026 FDA has no questions (in PDF) (240 kB)
  1302
Fermented grape pomace Pending
  1301
Algal oil (≥45% docosahexaenoic acid from Schizochytrium sp. JDW-108) Pending
  1300
Zeaxanthin produced via fermentation using production strain Yarrowia lipolytica CGMCC 39021 May 15, 2026 FDA has no questions (in PDF) (194 kB)
  1299
3′-sialyllactose sodium salt produced via fermentation using production strain Escherichia coli “SLIS109” May 13, 2026 FDA has no questions (in PDF) (299 kB)
  1298
2'-fucosyllactose Jun 23, 2026 FDA has no questions (in PDF) (335 kB)
  1297
Enzyme-hydrolyzed brown rice protein Pending
  1296
Erythritol produced through fermentation of glucose by Yarrowia lipolytica Apr 7, 2026 FDA has no questions (in PDF) (202 kB)
  1295
Brazzein preparation produced by Komagataella phaffii GS115 expressing a gene encoding for brazzein from Pentadiplandra brazzeana Jun 23, 2026 FDA has no questions (in PDF) (263 kB)
  1294
Rebaudioside M produced by enzymatic treatment of steviol glycosides purified from the leaves of Stevia rebaudiana (Bertoni) Bertoni Apr 16, 2026 FDA has no questions (in PDF) (191 kB)
  1293
Brazzein preparation produced by Komagataella phaffii RA-b expressing a gene encoding for brazzein from Pentadiplandra brazzeana Jun 23, 2026 FDA has no questions (in PDF) (199 kB)
  1292
Citrus-derived compounded sweetener made with neohesperidin dihydrochalcone and gamma cyclodextrin Apr 28, 2026 FDA has no questions (in PDF) (631 kB)
  1291
Wattle (Acacia longifolia) seeds Pending
  1290
Glucose oxidase enzyme preparation produced by Komagataella phaffii expressing a gene encoding glucose oxidase from Aspergillus niger May 6, 2026 FDA has no questions (in PDF) (201 kB)
  1289
Protein-glutamine glutaminase enzyme preparation produced by Bacillus licheniformis expressing a gene encoding protein-glutamine glutaminase from Chryseobacterium viscerum Jun 30, 2026 FDA has no questions (in PDF) (216 kB)
  1288
Enzyme-modified steviol glycosides Feb 17, 2026 FDA has no questions (in PDF) (220 kB)
  1287
Sucrose oligoesters Mar 23, 2026 FDA has no questions (in PDF) (234 kB)
  1286
Brazzein preparation produced by Zea mays expressing a gene encoding for brazzein from Pentadiplandra brazzeana Jun 30, 2026 FDA has no questions (in PDF) (286 kB)
  1285
Saccharomyces cerevisiae BY-927 expressing a gene encoding α-acetolactate decarboxylase enzyme from Acetobacter aceti Mar 9, 2026 FDA has no questions (in PDF) (255 kB)
  1284
Recombinant bovine lactoferrin isolate produced by Komagataella phaffii Ppas_337 expressing the gene encoding bovine lactoferrin Mar 25, 2026 FDA has no questions (in PDF) (201 kB)
  1283
Bacillus coagulans BC99 spore preparation Mar 18, 2026 FDA has no questions (in PDF) (256 kB)
  1282
Rebaudioside M produced by enzymatic treatment of rebaudioside A purified from the leaves of Stevia rebaudiana (Bertoni) Bertoni Jan 12, 2026 FDA has no questions (in PDF) (257 kB)
  1281
2'-Fucosyllactose May 8, 2026 Notice does not provide a basis for a GRAS determination (in PDF) (198 kB)
  1280
Pleurotus pulmonarius mycelia and Chlorella vulgaris microalgae Pending
  1279
Saccharomyces cerevisiae CCTCC M2025194 Mar 23, 2026 FDA has no questions (in PDF) (189 kB)
  1278
Lactiplantibacillus plantarum CGMCC 6312 Mar 31, 2026 FDA has no questions (in PDF) (291 kB)
  1277
Autoclaved Parabacteroides goldsteinii RV-01 Jan 22, 2026 At the notifier's request, FDA ceased to evaluate this notice (in PDF) (293 kB)
  1276
Cellulase enzyme preparation produced by Trichoderma reesei expressing a gene encoding a cellulase from Aspergillus niger Apr 8, 2026 FDA has no questions (in PDF) (260 kB)

Show All 

jump to page of 27 


GRN No.
(sorted Z-A)
Substance Date of closure FDA's Letter Date of add'l correspondence Resubmitted as GRN No.
-
-